Seres Therapeutics, Inc.
MCRB
DELAYED 1 MONTH
9 insider filings · Latest: May 15, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | May 19 8:05 PM | Thomas DesrosierEVP and Chief Legal Officer | Sale | 79 | $7.53 | $595 | 7,954(D) | View → |
| May 18, 2026 | May 19 8:05 PM | Eric D. ShaffDirector | Sale | 259 | $7.53 | $2.0K | 12,040(D) | View → |
| May 18, 2026 | May 19 8:05 PM | Matthew R HennChief Scientific Officer and EVP | Sale | 77 | $7.53 | $580 | 7,838(D) | View → |
| May 18, 2026 | May 19 8:05 PM | Kelly BradyChief Operating Officer, EVP | Sale | 59 | $7.53 | $444 | 8,562(D) | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | May 19 8:05 PM | Eric D. ShaffDirector | Option Exercise | 722 | — | 2,325(D) | View → |
| May 15, 2026 | May 19 8:05 PM | Thomas DesrosierEVP and Chief Legal Officer | Option Exercise | 244 | — | 779(D) | View → |
| May 15, 2026 | May 19 8:05 PM | Matthew R HennChief Scientific Officer and EVP | Option Exercise | 238 | — | 683(D) | View → |
| May 15, 2026 | May 19 8:05 PM | Kelly BradyChief Operating Officer, EVP | Option Exercise | 180 | — | 639(D) | View → |
| Mar 4, 2026 | Mar 11 10:39 PM | Kelly BradyChief Operating Officer, EVP | Grant/Award | 56,250 | $9.13 | 56,250(D) | View → |
| Mar 4, 2026 | Mar 6 9:36 PM | Richard N KenderDirector, Interim Chief Executive Officer | Grant/Award | 150,000 | $9.13 | 150,000(D) | View → |
| Mar 4, 2026 | Mar 6 9:35 PM | Matthew R HennPresident and Chief Scientific Officer | Grant/Award | 75,000 | $9.13 | 75,000(D) | View → |
| Mar 4, 2026 | Mar 6 9:33 PM | Marella ThorellEVP and Chief Financial Officer | Grant/Award | 22,500 | $9.13 | 22,500(D) | View → |
| Mar 4, 2026 | Mar 6 9:31 PM | Thomas DesrosierEVP and Chief Legal Officer | Grant/Award | 22,500 | $9.13 | 22,500(D) | View → |